CancerNetwork Members: Login | Register
    

 
NEWS
2007 Transmittals | Center for Medicare & Medicaid Services
www.cms.gov - 4/23/12
Prostate Cancer
emedicine.medscape.com - 4/23/12
Prostate Cancer Study: Update to PSA Screening Data Renews Controversy
www.cancernetwork.com - 3/15/12
 
PRACTICE GUIDELINES
Guide to Clinical Preventive Services, 2010-2011: Section 2
www.ahrq.gov - 9/1/10
Figure 2. Percentage of participants who did and did not plan to obtain PSA screening in the future according to PSA screening history.
www.acponline.org -
Table 3. Underlying Beliefs Cited by Men Regardless of Plan for Future PSA Screening
www.acponline.org -
 
JOB LISTINGS

Post a job

Powered by SearchMedica Jobs
 
FOR PATIENTS
Prostate Cancer: MedlinePlus
www.nlm.nih.gov - 4/30/12
Tumor markers
ghr.nlm.nih.gov - 4/24/12
Articles of Interest, March 30, 2012
www.ahrq.gov - 4/16/12

 

Order Your Copy!
(2010, 13th Edition)

 


 

Please allow 3 – 4 weeks to ship
 
CONNECT WITH US
Become a fan on
Facebook
Add us on
Google Plus
Follow us on
Twitter
Join us on
LinkedIn
Sign up for our
Newsletters
Subscribe to our
RSS Feed


PSA Screening
 
LATEST FEATURES
March 15, 2012
Prostate Cancer Study: Update to PSA Screening Data Renews Controversy
Rationale for prostate cancer screening continues to be debated as an update to a large European trial reconfirms a reduction in death rates from prostate cancer in men who are screened for the disease. The study, however, found no significant difference in overall mortality between the two arms of the trial. More »
November 21, 2011
Perspectives on the New PSA Screening Recommendations
This is a very emotional issue. Any time a group claims less screening is good, I always take it with a grain of salt—yet the data certainly seem to support that generalized screening with PSA may not impact survival in the general population. More »
October 20, 2011
Video: Overview of PSA Testing
A video series from James Mohler of Rosweel Park Cancer Institute on PSA testing in the wake of changing guidelines from the US Preventive Task Force. More »
October 19, 2011
The Benefits of PSA Testing
James Mohler, Roswell Park Cancer Institute, responds to recommendations from the US Preventive Services Taskforce to limit PSA testing by pointing out the benefits. More »
October 19, 2011
Video: The Risks of PSA Screening
Roswell Park Cancer Institue's James Mohler, MD, on the risks of PSA screening More »
Showing 1 - 5 of 71 results.
Page of 15
First Previous Last
 
MEDLINE
New data on prostate-cancer mortality after PSA screening.
pubmed.gov - 3/15/12
22417259 2012 03 15 2012 03 22 1533-4406 366 11 Mar 15 N. Engl. J. Med. 1047-8 Miller Anthony B AB eng Comment Editorial United States N Engl J Med 0255562 0028-4793 EC 3.4.21.77 Prostate-Specific Antigen AIM IM N Engl J Med. 2012 Mar 15; 366( 11):
USPSTF finds little evidence to support advising PSA screening in any man.
pubmed.gov - 12/21/11
22187266 2011 12 21 2011 12 23 1538-3598 306 23 Dec 21 JAMA 2549-51 Slomski Anita A eng News United States JAMA 7501160 0098-7484 EC 3.4.21.77 Prostate-Specific Antigen AIM IM standards blood diagnosis ethnology mortality pathology epidemiology
Celebrating the death of PSA screening?
pubmed.gov - 12/2/11
22166323 2011 12 14 2012 04 26 1195-9479 18 6 Dec Can J Urol 5987 Gomella Leonard G LG eng Editorial Canada Can J Urol 9515842 1195-9479 EC 3.4.21.77 Prostate-Specific Antigen IM methods trends blood blood diagnosis epidemiology trends epidemiology
The EPI bioassay identifies natural compounds with estrogenic activity that are potent inhibitors of androgenic pathways in human prostate stromal and epithelial cells.
pubmed.gov - 4/2/12
The reactive stromal phenotype is an important factor for prostate cancer progression and may be a new target for treatment and prevention. A new high efficiency preclinical protocol, the EPI bioassay, reflects the interaction of endocrine, paracrine and immune, (EPI) factors on induced androgen metabolism in human prostate reactive stroma. The bioassay is based on co-culturing human primary prostate stromal cells and LAPC-4 prostatic adenocarcinoma cells in a downscaled format of 96-well-plates for testing multiple doses of multiple target compounds. Metabolism of dehydroepiandrosterone (DHEA) with or without TGF1-induced stimulation (D+T) of the reactive stroma phenotype was assessed by increased testosterone in the media and PSA production of the epithelial prostate cancer cells. Using the non-metabolizable androgen R1881, effects from direct androgen action were distinguished from stromal androgen production from DHEA. Stromal cell androgenic bioactivity was confirmed using
Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer.
pubmed.gov - 4/2/12
To investigate the outcomes and potential effect of improved longitudinal screening in men presenting with high-risk (advanced clinical stage [>T2b], Gleason score 8-10 or prostate-specific antigen [PSA] level >20 ng/mL) prostate cancer (PC).|The Institutional Review Board approved, Institutional Radical Prostatectomy Database (1992-2010) was queried for men with high-risk PC based on D'Amico criteria. Year of surgery was divided into two cohorts: the Early PSA Era (EPE, 1992-2000) and the Contemporary PSA Era (CPE, 2001-2010). PC features and outcomes were evaluated using appropriate comparative tests.|In total, 667 men had high-risk PC in the EPE and 764 in the CPE. In the EPE, 598 (89.7%) men presented with one high-risk feature; 173 (29.0%) men had a Gleason score of 8-10 on biopsy. In the CPE, 717 (93.9%) men presented with one high-risk feature (P = 0.004) and 494 (68.9%) men had a Gleason score of 8-10. At 10 years, biochemical-free survival (BFS) was 44.1% and 36.4% in the EPE
 
CLINICAL TRIALS
Prostate Cancer Screening and Dietary Heterocyclic Amines in African American Men
www.clinicaltrials.gov -
Facilitating Shared Decisionmaking About Prostate Cancer Screening
www.clinicaltrials.gov -
Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
www.clinicaltrials.gov -
Follow-Up Study for Men Diagnosed With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program
www.clinicaltrials.gov -
Study of Individualized Amonafide to Treat Prostate Cancer
www.clinicaltrials.gov -



 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 
 
FROM PHYSICIANS PRACTICE
Physician Performance Goals Are Great, But Balance Is More Realistic
Jennifer Frank, MD,  May 15, 2012
Performance measurements for physicians are well-intentioned and get me to rethink how I practice. But in the end I won't make the goals, so I'll have to go with balance over perfection.
Designing the Perfect Business Card for Your Medical Practice
C. Noel Henley, MD,  May 11, 2012
Does your business card say anything substantive about the valuable work you do in your practice? Here’s how to re-design your next business card for maximum impact and engagement.
Registered Nurses an Ideal Fit for Primary Care Practices
Audrey "Christie" McLaughlin, RN,  May 10, 2012
Here are four good reasons to hire a registered nurse for your primary care practice …maybe even instead of a medical assistant.
The Five Biggest Medical Practice Marketing Mistakes
James Doulgeris,  May 10, 2012
There are best practices to marketing your practice, but often, success is more about knowing what not to do. Here are the five most common pitfalls …and how to avoid them.
Can You Practice Medicine and Manage Your Practice?
Rosemarie Nelson,  May 9, 2012
Whether you practice alone, or in a group, if you're trying to see patients in this pay-for-volume environment and also run the business of your practice, you may be missing out on important opportunities.
 
COMMENTS